HRP20191396T1 - Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze - Google Patents
Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze Download PDFInfo
- Publication number
- HRP20191396T1 HRP20191396T1 HRP20191396T HRP20191396T1 HR P20191396 T1 HRP20191396 T1 HR P20191396T1 HR P20191396 T HRP20191396 T HR P20191396T HR P20191396 T1 HRP20191396 T1 HR P20191396T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazol
- tautomer
- stereoisomer
- solvate
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968 | 2015-04-02 | ||
| PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
| EP16717560.3A EP3277681B1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191396T1 true HRP20191396T1 (hr) | 2019-11-01 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191396 HRP20191396T1 (hr) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze |
| HRP20210981TT HRP20210981T1 (hr) | 2015-04-02 | 2021-06-23 | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210981TT HRP20210981T1 (hr) | 2015-04-02 | 2021-06-23 | Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (enExample) |
| EP (3) | EP3277681B1 (enExample) |
| JP (2) | JP6791873B2 (enExample) |
| KR (2) | KR20240044525A (enExample) |
| CN (3) | CN111689963A (enExample) |
| AU (4) | AU2016239270B2 (enExample) |
| BR (1) | BR122019005502B1 (enExample) |
| DK (2) | DK3560924T3 (enExample) |
| ES (3) | ES2880626T3 (enExample) |
| HR (2) | HRP20191396T1 (enExample) |
| HU (2) | HUE054745T2 (enExample) |
| IL (3) | IL254714B (enExample) |
| LT (2) | LT3560924T (enExample) |
| MX (2) | MX390537B (enExample) |
| PL (2) | PL3560924T3 (enExample) |
| PT (2) | PT3277681T (enExample) |
| RS (2) | RS59139B1 (enExample) |
| RU (1) | RU2743343C2 (enExample) |
| SG (2) | SG10202002181UA (enExample) |
| SI (2) | SI3277681T1 (enExample) |
| TR (1) | TR201911244T4 (enExample) |
| WO (1) | WO2016155884A1 (enExample) |
| ZA (1) | ZA201707423B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3560924T3 (da) * | 2015-04-02 | 2021-06-28 | Merck Patent Gmbh | Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| EP3737383A4 (en) | 2018-01-12 | 2021-12-15 | Prolynx LLC | SYNERGISTIC CANCER TREATMENT |
| JP2021517145A (ja) * | 2018-03-14 | 2021-07-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 対象の腫瘍を治療するための化合物およびその使用 |
| ES2965174T3 (es) | 2018-04-12 | 2024-04-11 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| MX391410B (es) * | 2018-09-30 | 2025-03-21 | Medshine Discovery Inc | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. |
| IL325102A (en) * | 2019-03-27 | 2026-02-01 | Merck Patent Gmbh | History of Imidazolonylquinilines and their medical uses |
| EP4003345B1 (en) * | 2019-07-30 | 2024-12-04 | XRad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CA3154413A1 (en) * | 2019-11-01 | 2021-05-06 | Yan Lan | Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer |
| EP4069366B1 (en) | 2019-12-04 | 2025-03-19 | CHDI Foundation, Inc. | Atm kinase inhibitors and compositions and methods of use thereof |
| WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| JP2023530004A (ja) * | 2020-06-18 | 2023-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルス感染症の処置のための化合物 |
| EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
| AU2021346097A1 (en) | 2020-09-18 | 2023-03-09 | Merck Patent Gmbh | Pharmaceutical preparation |
| EP4142710B1 (en) | 2020-09-21 | 2024-01-31 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
| CN120418259A (zh) * | 2022-11-23 | 2025-08-01 | 弗沃德医疗公司 | TNFα活性的调节剂 |
| WO2025157979A1 (en) | 2024-01-26 | 2025-07-31 | Merck Patent Gmbh | Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one |
| TW202547476A (zh) | 2024-04-03 | 2025-12-16 | 美商弗沃德醫療公司 | TNF-α活性調節劑 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| CA2601542C (en) * | 2005-03-21 | 2012-09-18 | Ferrer Internacional, S.A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7598273B2 (en) * | 2005-10-06 | 2009-10-06 | Auspex Pharmaceuticals, Inc | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| RU2478387C2 (ru) | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| EP2474323A3 (en) | 2008-03-26 | 2012-10-10 | Novartis AG | Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| RU2015105591A (ru) * | 2008-06-10 | 2015-08-10 | Эббви Инк. | Новые трициклические соединения |
| WO2010037715A1 (en) | 2008-10-01 | 2010-04-08 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| GEP20156267B (en) | 2009-06-04 | 2015-04-14 | Novartis Ag | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| MX2012010557A (es) * | 2010-03-16 | 2012-10-05 | Merck Patent Gmbh | Morfolinilquinazolinas. |
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| KR20140010009A (ko) | 2010-12-03 | 2014-01-23 | 노파르티스 아게 | 제약 조성물 |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| RU2014154009A (ru) | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
| NO2714752T3 (enExample) | 2014-05-08 | 2018-04-21 | ||
| DK3560924T3 (da) * | 2015-04-02 | 2021-06-28 | Merck Patent Gmbh | Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer |
-
2016
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Pending
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 MX MX2020011558A patent/MX390537B/es unknown
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active Active
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de not_active Ceased
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 MX MX2017012613A patent/MX376947B/es active IP Right Grant
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
-
2025
- 2025-01-20 AU AU2025200385A patent/AU2025200385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240650T1 (hr) | Spojevi imidazolonilkinolina i njihova terapeutska upotreba | |
| JP2018510191A5 (enExample) | ||
| ES2741853T3 (es) | Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa | |
| ES2948949T3 (es) | Inhibidores de la interacción menina-MLL | |
| US10500193B2 (en) | Combination therapy of HSP90 inhibitors with platinum-containing agents | |
| HRP20202058T1 (hr) | Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma | |
| ES2629932T3 (es) | Inhibidor de PFKFB3 y métodos de uso como terapéutico contra el cáncer | |
| UA126177C2 (uk) | Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази | |
| US20180303829A1 (en) | Method for treating cancer using a combination of dna damaging agents and atr inhibitors | |
| RU2012153675A (ru) | Соединения, пригодные в качестве ингибиторов atr киназы | |
| SI2376485T1 (en) | PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS | |
| IL257847A (en) | Derivatives of 8– [6– [3 [- (amino) propoxy] –3 – pyridyl] –1 – isopropyl – imidazo [4, 5 –c] quinoline – 2 – ion as selective kinases of kinase atm for cancer treatment | |
| SI2833973T1 (en) | Compounds useful as inhibitors of ATR kinase and their combination therapy | |
| PE20081379A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| US10053478B2 (en) | COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2013213055A5 (enExample) | ||
| HRP20201944T1 (hr) | Inhibitori kinaze povezane sa tropomiozinom (trk) | |
| JP2013523814A5 (enExample) | ||
| CA3054247A1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| RU2704120C2 (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| CA3214747A1 (en) | Combination therapies for the treatment of cancer | |
| BR112014022266A2 (pt) | Combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com outros compostos antitumor | |
| RU2015153834A (ru) | ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| SI3030554T1 (en) | PIPERIDIN-SEA DERIVATIVES |